Response to letter entitled re: UGT1A1 genotype-guided dosing of irinotecan: A prospective safety and cost analysis in poor metaboliser patients: Is it time for everyone treated with irinotecan to be tested for UGT1A1 gene polymorphism?

Emma C. Hulshof; Mirjam de With; Geert Jan Creemers; Henk Jan Guchelaar; Ron HJ Mathijssen; Hans Gelderblom; Maarten J. Deenen

doi:10.1016/j.ejca.2022.05.045

Response to letter entitled re: UGT1A1 genotype-guided dosing of irinotecan: A prospective safety and cost analysis in poor metaboliser patients: Is it time for everyone treated with irinotecan to be tested for UGT1A1 gene polymorphism?

Emma C. Hulshof
, Mirjam de With
, Geert Jan Creemers
, Henk Jan Guchelaar
, Ron HJ Mathijssen
, Hans Gelderblom
, Maarten J. Deenen^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Original language	English
Pages (from-to)	231-233
Number of pages	3
Journal	European Journal of Cancer
Volume	172
DOIs	https://doi.org/10.1016/j.ejca.2022.05.045
Publication status	Published - Sept 2022

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.ejca.2022.05.045Licence: Unspecified

Cite this

Hulshof, E. C., de With, M., Creemers, G. J., Guchelaar, H. J., Mathijssen, R. HJ., Gelderblom, H., & Deenen, M. J. (2022). Response to letter entitled re: UGT1A1 genotype-guided dosing of irinotecan: A prospective safety and cost analysis in poor metaboliser patients: Is it time for everyone treated with irinotecan to be tested for UGT1A1 gene polymorphism? European Journal of Cancer, 172, 231-233. https://doi.org/10.1016/j.ejca.2022.05.045

@article{7683fab9f3fa4320a6b603749fa30baa,

title = "Response to letter entitled re: UGT1A1 genotype-guided dosing of irinotecan: A prospective safety and cost analysis in poor metaboliser patients: Is it time for everyone treated with irinotecan to be tested for UGT1A1 gene polymorphism?",

author = "Hulshof, \{Emma C.\} and \{de With\}, Mirjam and Creemers, \{Geert Jan\} and Guchelaar, \{Henk Jan\} and Mathijssen, \{Ron HJ\} and Hans Gelderblom and Deenen, \{Maarten J.\}",

year = "2022",

month = sep,

doi = "10.1016/j.ejca.2022.05.045",

language = "English",

volume = "172",

pages = "231--233",

journal = "European Journal of Cancer",

issn = "0959-8049",

publisher = "Elsevier Ltd.",

}

Hulshof, EC, de With, M, Creemers, GJ, Guchelaar, HJ, Mathijssen, RHJ, Gelderblom, H & Deenen, MJ 2022, 'Response to letter entitled re: UGT1A1 genotype-guided dosing of irinotecan: A prospective safety and cost analysis in poor metaboliser patients: Is it time for everyone treated with irinotecan to be tested for UGT1A1 gene polymorphism?', European Journal of Cancer, vol. 172, pp. 231-233. https://doi.org/10.1016/j.ejca.2022.05.045

Response to letter entitled re: UGT1A1 genotype-guided dosing of irinotecan: A prospective safety and cost analysis in poor metaboliser patients: Is it time for everyone treated with irinotecan to be tested for UGT1A1 gene polymorphism? / Hulshof, Emma C.; de With, Mirjam; Creemers, Geert Jan et al.
In: European Journal of Cancer, Vol. 172, 09.2022, p. 231-233.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Response to letter entitled re

T2 - UGT1A1 genotype-guided dosing of irinotecan: A prospective safety and cost analysis in poor metaboliser patients: Is it time for everyone treated with irinotecan to be tested for UGT1A1 gene polymorphism?

AU - Hulshof, Emma C.

AU - de With, Mirjam

AU - Creemers, Geert Jan

AU - Guchelaar, Henk Jan

AU - Mathijssen, Ron HJ

AU - Gelderblom, Hans

AU - Deenen, Maarten J.

PY - 2022/9

Y1 - 2022/9

UR - https://www.scopus.com/pages/publications/85133484697

U2 - 10.1016/j.ejca.2022.05.045

DO - 10.1016/j.ejca.2022.05.045

M3 - Article

C2 - 35793611

AN - SCOPUS:85133484697

SN - 0959-8049

VL - 172

SP - 231

EP - 233

JO - European Journal of Cancer

JF - European Journal of Cancer

ER -

Hulshof EC, de With M, Creemers GJ, Guchelaar HJ, Mathijssen RHJ, Gelderblom H et al. Response to letter entitled re: UGT1A1 genotype-guided dosing of irinotecan: A prospective safety and cost analysis in poor metaboliser patients: Is it time for everyone treated with irinotecan to be tested for UGT1A1 gene polymorphism? European Journal of Cancer. 2022 Sept;172:231-233. doi: 10.1016/j.ejca.2022.05.045

Response to letter entitled re: UGT1A1 genotype-guided dosing of irinotecan: A prospective safety and cost analysis in poor metaboliser patients: Is it time for everyone treated with irinotecan to be tested for UGT1A1 gene polymorphism?

UN SDGs

Access to Document

Other files and links

Cite this